Details

Autor(en) / Beteiligte

• Shah, Jenny
• Muir, Justin
• Furfaro, David
• Beitler, Jeremy R.
• Dzierba, Amy L.

Titel

Use of N-Acetylcysteine for Clozapine-Induced Acute Liver Injury: A Case Report and Literature Review

Ist Teil von

• Journal of pharmacy practice, 2023-04, Vol.36 (2), p.463-467

Ort / Verlag

Los Angeles, CA: SAGE Publications

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose: To report a case of clozapine-induced hepatotoxicity managed with intravenous (IV) N-acetylcysteine (NAC) and summarize the available literature. Summary: A 46-year-old woman with history of bipolar disorder with psychotic features presented to the intensive care unit with asterixis and elevations in liver enzymes. The patient had been initiated on risperidone, clozapine, and lithium approximately 1 month prior to admission. After ruling out other possible non-drug etiologies, clozapine was suspected as the likeliest cause of the acute liver injury. Her acute liver injury was managed with the discontinuation of all antipsychotics, administration of IV NAC, and other standard of care supportive measures. Conclusion: Although clozapine has been associated with hepatitis and acute liver failure, there are no reports of NAC used in the management of clozapine-induced hepatotoxicity. NAC was used in our patient after considering the potential benefit and limited adverse effects. The role of NAC in non–acetaminophen-induced acute liver failure remains promising, but more research is warranted.